November 2013 Volume 9, Issue 11

Volume 9, Issue 11 | November 2013

November 2013

In this Issue

Government Watch

Drug Discovery News Placeholder Image

Science under siege

Already facing tough decisions caused by the sequestration, the U.S. government shutdown further stymies American biomedical researchers
Drug Discovery News Placeholder Image

Supreme Court silences Novartis

High court declines to hear case questioning whether punitive damages should be awarded in product liability lawsuits
Drug Discovery News Placeholder Image

The element of surprise

FDA to begin unannounced site inspections at Indian facilities
Drug Discovery News Placeholder Image

California governor vetoes controversial biosimilars bill

Similar measures pending in several states before FDA has even issued regulatory guidelines

Global News

Drug Discovery News Placeholder Image

Seeking to streamline

Workforce reductions common as pharma industry aims to restructure
Drug Discovery News Placeholder Image

Collaborators launch clinical trial for cystic fibrosis

Galapagos signs $405 million deal with AbbVie to develop new combination therapies for chronic disease
Drug Discovery News Placeholder Image

An oral agreement

Novo Nordisk and Oramed both pour great effort into promise of oral insulin
Drug Discovery News Placeholder Image

From iPS to hepatocytes

Japanese researchers develop new, faster method of hepatocyte generation
Drug Discovery News Placeholder Image

Long-term vision

Acino anticipates buyout by private equity firms for $439 million

Research & Development

Drug Discovery News Placeholder Image

All together now …

IMPROVER launches new challenge, as other major life-science group efforts also continue their own work
Drug Discovery News Placeholder Image

Sealing the deal

After no small amount of controversy, Otsuka reports that it has completed its acquisition of Astex
Drug Discovery News Placeholder Image

HμREL liver tissue co-culture to be tested by Sanofi

Goal is to validate HμRELhuman for use in preclinical drug development
Drug Discovery News Placeholder Image

Academic institutions partner with Takeda in landmark collaboration

MSKCC, Rockefeller University and Weill Cornell to conduct early-stage drug discovery with pharma
Drug Discovery News Placeholder Image

Joslin partners with Pfizer, Lilly on diabetes

Companies will predict, treat kidney failure in type 2 diabetes

Omics & Systems Biology

Drug Discovery News Placeholder Image

Going GLOBAL

Illumina, G3 team up on massive pan-omic cardiovascular study
Drug Discovery News Placeholder Image

Going large with the liver

TGen-led GWAS study identifies genes associated with unhealthy liver function
Drug Discovery News Placeholder Image

A messenger with punch

CureVac, Janssen partner to develop mRNA-based influenza vaccine
Drug Discovery News Placeholder Image

Finding significant DNA mutations

Dozens of cancer triggers identified and ranked using new tool that scans conserved regions of non-coding DNA

Commentary

Drug Discovery News Placeholder Image

Cell sorting for everyone: From the core lab to your lab

When cell-sorting technology first arrived in the late 1970s, it was used by academics and the medical research community to detect, count and characterize cells from the body and environment. As cell-sorting technology evolved and improved, it also became more complex, unfortunately making it less accessible to many researchers. Fortunately, recent advances in instrumentation have led to the development of much smaller, significantly less expensive and much easier-to-use cell-sorting devices, meaning that even basic researchers can now access this useful technology.
Drug Discovery News Placeholder Image

Out of Order: Having words

It can be difficult at times, when discussing various aspects of the pharmaceutical and biotechnology industries, to remember that at the very base of the process is someone who is hurting and afraid. Not a patient population from a clinical trial who act in a statistical manner, but a single individual with his or her own experiences, biases and concerns.

Editor's Focus

Drug Discovery News Placeholder Image

It's time now to sing out, though the story never ends

2,832 pages: How do you measure, measure five years? This editorial column will be my last in Drug Discovery News, as in a few short weeks, I will be stepping down from my post as chief editor of the news organization and entering a new chapter in my life. As I clean up my office and prepare to pass the baton to Jeff Bouley, who will be your new chief editor in 2014, I am reflecting with great fondness some of the amazing people I have met and the remarkable experiences I have had in the past five and a half years of leading our editorial team in the creation of these pages. Thus, as I exit stage left, I will take inspiration from the song “Seasons of Love” from the hit musical “Rent” (which explains my headline and lead, if you’re not familiar with it) and recall some of the memorable ways in which I will measure my tenure.

Diagnostics

Drug Discovery News Placeholder Image

Accelerating solutions

Pacific Biosciences-Roche Diagnostics agreement aims to take DNA sequencing-based products to the clinic
Drug Discovery News Placeholder Image

Linking lipid metabolism

Researchers to study how lipid metabolism links psychotic disorders, metabolic co-morbidities
Drug Discovery News Placeholder Image

Business at light speed

Biosearch Technologies acquires majority stake in LightSpeed Genomics
Drug Discovery News Placeholder Image

Epigenomics announces completion of private placement, new partnerships

The proceeds from the offering are slated to finance Epigenomics’ current operations and to build and bolster its distribution capacities for its lead product Epi proColon

News Briefs

Drug Discovery News Placeholder Image

Evotec teams with Johnson & Johnson Innovation to identify novel Alzheimer's Disease therapies

Evotec AG announced its second major collaboration in recent weeks, this time with the Johnson & Johnson Innovation Center in California to identify new targets for Alzheimer's disease drug discovery and development. Under the terms of the agreement, Janssen Pharmaceuticals, Inc., a member of the Johnson & Johnson family of companies, and Evotec will work together to discover and develop novel treatments for Alzheimer's disease.

Special Reports

Drug Discovery News Placeholder Image

Reinventing medicinal chemistry

New technologies and attitudes offer medicinal chemists an evolving role in drug discovery

Feature

Drug Discovery News Placeholder Image

ASCB Annual Meeting Preview: Developing talent

In addition to high-level educational fare, ASCB looks to step up professional development offerings at its annual meeting

Tools & Technology

Drug Discovery News Placeholder Image

Bruker acquires Prairie Technologies

Acquisition strengthens Bruker Nano Surfaces Division's position in life-science markets
Drug Discovery News Placeholder Image

A 'model' new research center

Bayer and RWTH Aachen University create center for computer-based modeling
Drug Discovery News Placeholder Image

Sad news for cancer

Stanford-led research uses bioinformatics approach to identify antidepressant that could be cancer-fighter
Drug Discovery News Placeholder Image

Now hear this

Labcyte teams with AstraZeneca to develop acoustic sample handling for mass spectrometry to advance drug discovery
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue